Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665142 | 0.84 | ALDH1A1 (0.64) | TAAR1ALDH1A1MMP1POLBMMP2 | |
| SCHEMBL4017341 | 0.80 | ALDH1A1 (1.00) | TAAR1ALDH1A1MMP1POLBMMP2 | |
| SCHEMBL6891812 | 0.80 | ALDH1A1 (1.00) | TAAR1ALDH1A1MMP1POLBMMP2 | |
| SCHEMBL4017350 | 0.80 | ALDH1A1 (1.00) | TAAR1ALDH1A1MMP1POLBMMP2 | |
| SCHEMBL15494538 | 0.79 | TAAR1 (0.73) | TAAR1ALDH1A1MMP1POLBMMP2 | |
| SCHEMBL15431342 | 0.79 | TAAR1 (0.73) | TAAR1ALDH1A1MMP1POLBMMP2 | |
| SCHEMBL10844688 | 0.71 | SMN1; SMN2 (0.54) | TAAR1ALDH1A1MMP1POLBMMP2 | |
| SCHEMBL10843294 | 0.71 | MAPT (0.65) | ALDH1A1MAPTMEN1KMT2ACACNA1B | |
| SCHEMBL10709429 | 0.71 | SMN1; SMN2 (0.54) | TAAR1ALDH1A1MMP1POLBMMP2 | |
| SCHEMBL10709043 | 0.71 | MAPT (0.65) | ALDH1A1MAPTMEN1KMT2ACACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | TAAR1 3910/4885ALDH1A1 3714/4885MMP1 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.